Narrative Review: Risk-Benefit Hydroxychloroquine and Chloroquine in COVID-19
Chloroquine (CQ) and Hydroxychloroquine (HCQ) are highly prescribed as medications for COVID-19 infection, although no robust or convincing data has yet been published about the efficacy in COVID-19 patients. Therefore, risk and benefit assessment are necessary for decision to prescribe these drugs...
Main Author: | Jarir At Thobari |
---|---|
Format: | Article |
Language: | English |
Published: |
Universitas Gadjah Mada
2021-08-01
|
Series: | Indonesian Journal of Pharmacy |
Subjects: | |
Online Access: | https://jurnal.ugm.ac.id/v3/IJP/article/view/1187 |
Similar Items
-
Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety
by: Michael Takla, et al.
Published: (2020-12-01) -
Clinical Efficacy of Hydroxychloroquine or Chloroquine in Patients with COVID-19: An Umbrella Review
by: Kavous Shahsavarinia, et al.
Published: (2021-12-01) -
Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use
by: Yan Chen, et al.
Published: (2020-07-01) -
Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine
by: Babayeva M, et al.
Published: (2020-10-01) -
Caution of retinal toxicity using chloroquine and hydroxychloroquine in the treatment of COVID-19
by: Li-Yuan Wang, et al.
Published: (2020-07-01)